Clinical Trial Update: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating RO4929097 with paclitaxel and carboplatin before surgery in stage II/III triple-negative breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Status: TERMINATED